Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Flow cytometric immunophenotyping is crucial for diagnosing and prognosticating plasma cell dyscrasias.
• Understanding plasma cell immunophenotype and ploidy status is vital for myeloma management.

Purpose of the Study:

• To evaluate the immunophenotype and ploidy status of plasma cells in myeloma patients.
• To correlate these findings with laboratory parameters and assess prognostic potential.

Main Methods:

• Bone marrow samples from 70 newly diagnosed myeloma patients were analyzed using flow cytometry.
• A panel of antibodies including CD138, CD38, CD19, CD45, CD28, CD81, CD56, CD200, and CD229 was employed.
• FxCycle Violet dye was used for ploidy analysis of clonal plasma cells.

Main Results:

• A positive correlation was found between morphological and FCM-based plasma cell enumeration.
• Aberrant expression of CD56 (88.5%), CD200 (77%), and CD81 (23%) was frequently observed.
• Hyperdiploid plasma cells were identified in 80% of cases; CD81 expression correlated with higher monoclonal protein and renal insufficiency.
• CD229 was expressed in all cases and is a reliable gating marker; CD56/CD200 and CD45- can identify abnormal plasma cells.

Conclusions:

• Flow cytometry immunophenotyping and ploidy analysis provide valuable diagnostic and prognostic information in myeloma.
• CD81 may serve as a prognostic marker, correlating with disease burden.
• Ploidy analysis can aid in identifying patients with poor prognosis and should be considered in routine workup.